Article
A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma
30 May 2024
Abstract excerpt
Temozolomide (TMZ) is a widely utilized chemotherapy treatment for patients with glioblastoma (GBM), although drug resistance constitutes a major therapeutic hurdle. Emerging evidence suggests that ferroptosis-mediated therapy could offer an appropriate alternative treatment option against cancer cells that are resistant to certain drugs. However, recurrent gliomas display robust ferroptosis resistance, although...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
